Phase 1 Parallel Study of CLR 125 in Triple Negative Breast Cancer

Phase 1 Parallel Study of CLR 125 in Triple Negative Breast Cancer
Conditions: Breast Cancer

Interventions: Drug: Iopofosine I 131; Drug: CLR 125

Sponsors: Cellectar Biosciences, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 1, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments